Effect of Postvitrectomy Proactive Use of Conbercept on Postoperative Complications in PDR Patients

Peking University

Status and phase: Enrolling; Phase 2

Conditions: Proliferative Diabetic Retinopathy

Treatments: Drug: passive Anti-VEGF (conbercept) use; Drug: proactive Anti-VEGF (conbercept) use

Study type: Interventional

Funder types: Other

Identifiers

NCT05642793

PDR vitrectomy1

Details and patient eligibility

About

This is an unmasking randomized clinical trial. the main purpose of this study is to analyze whether posvitrectomy proactive use of conbercept can reduce the rate of postoperative complication in PDR patients.

Enrollment: 80 estimated patients

Sex: All

Ages: 19 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• PDR patients undergoing vitrectomy

Exclusion criteria

• patients who had received intravitreal injection or systemic use of all types of anti-VEGF agents in the recent three months before vitrectomy
• patients who had received intravitreal injection or systemic use of all types of steroid in the recent one month before vitrectomy
• patients who had received complete PRP before vitrectomy
• patients who are pregnant

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

80 participants in 2 patient groups

group 1 (proactive use of conbercept after vitrectomy)

Experimental group

Description:

proactive use of conbercept after vitrectomy

Treatment:

Drug: proactive Anti-VEGF (conbercept) use

group 2 (passive use of conbercept after vitrectomy)

Experimental group

Description:

passive use of conbercept after vitrectomy

Treatment:

Drug: passive Anti-VEGF (conbercept) use